The National Medical Products Administration granted conditional market approval to the Covid-19 vaccine developed by Sinopharm CNBG Beijing Institute. Before that, 5 countries had authorised emergency use for the said vaccine including China, the UAE, Bahrain, Egypt and Jordan. Abroad, over 10 heads of countries and government departments had received this vaccination. Up to now, over 50 countries had expressed the willingness to procure the vaccine.
Domestically, Sinopharm’s Covid-19 vaccines are being administered to priority groups of people in many places, with the number exceeding 1 million in Beijing and 602,000 in Shanghai. Over 10 million doses have been administered across the nation.